Chief Epidemiologist Þórólfur Guðnason has decided that Iceland will halt the use of the Moderna vaccine in Iceland. RÚV reports that the decision was made after reviewing new data from the Nordic countries, which shows an increased incidence of myocarditis, an inflammation of the heart muscle (or myocaridum), as well as pericarditis, an inflammation in the membrane surrounding the heart (or pericardium), among people vaccinated with Moderna.
The decision was announced on Friday on the website of the Directorate of Health.
Sweden currently restricts the use of Moderna to individuals who were born after 1991. Norway and Denmark recommend that Pfizer be used in lieu of Moderna for children aged 12 – 17. Iceland has echoed the latter recommendation, stating in a press release in August that “It is preferable to use the Pfizer/BioNTech vaccine for this age group in Iceland. The supply of this vaccine is the largest, the experience of using it for the age group is greater than with Moderna and it is easier to transport and use in smaller places all over the country, as there are fewer doses in each bottle than with Moderna.”
Friday’s announcement goes on to say that for the past two months, Moderna has almost exclusively been used for booster shots for those who received the single-shot Janssen [Johnson & Johnson] vaccine or for elderly or immunocompromised individuals who received a prior two-shot vaccination. Of those individuals whose first shot was Moderna, only a very few received a second shot that was also Moderna.
The Directorate of Health notes that Iceland has a sufficient supply of the Pfizer vaccine for booster shots for people with preexisting conditions and initial vaccination for those who have yet to be vaccinated. Pfizer’s vaccine will, therefore, be used while further information is sought on the safety of using Moderna for booster shots.
Around 20,000 Icelanders are fully vaccinated with Moderna.